Overview

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This is an extension study to evaluate the safety of Veliparib monotherapy or in combination with Carboplatin plus Paclitaxel or modified Folinic Acid/Fluorouracil/Irinotecan (FOLFIRI) in subjects with solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel
Veliparib